Wisconsin is currently home to 1280 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778
Recruiting
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2024
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Neoplasms
Register for Updates
Elimination of Minimal Residual Disease After Transplant
NCT05690984
Recruiting
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04069273
Recruiting
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Langlade Hospital and Cancer Center, Antigo, Wisconsin
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Healthy Little Eyes
NCT05971446
Recruiting
The purpose of this research study is to gather more information on how eye injury is related to a baby's future development and see if eye function and brain test results can be used, along with current measures, to better diagnose and treat babies with hypoxic-ischemic encephalopathy (HIE). Participants will undergo up to two eye exam sessions, involving both Visual Evoked Potential (VEP) and Electroretinogram (ERG) exams.
Gender:
ALL
Ages:
36 months and below
Trial Updated:
06/26/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy, Encephalopathy
Register for Updates
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
NCT05451771
Recruiting
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: AL Amyloidosis
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Columbia St. Mary's, Milwaukee, Wisconsin
Conditions: Breast Cancer
Register for Updates
Muscle Function After Childbirth
NCT05073224
Recruiting
This study will evaluate lower extremity and trunk neuromuscular control in 78 nulligravid and postpartum women. Participants will attend two experimental sessions, approximately 1 week apart, to assess neuromuscular function. Physical activity levels will also be assessed.
Gender:
FEMALE
Ages:
Between 20 years and 35 years
Trial Updated:
06/25/2024
Locations: Carroll University, Waukesha, Wisconsin
Conditions: Postpartum, Muscle Fatigue, Force Steadiness, Nulligravid, Muscle Weakness
Register for Updates
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
NCT04270175
Recruiting
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Register for Updates
Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes
NCT06279637
Recruiting
This study will test the preliminary efficacy of a joint patient/informal caregiver telephone-delivered intervention that includes diabetes education; problem solving around social needs; and behavioral activation for older African Americans with poorly controlled type 2 diabetes by randomizing 100 patient/caregiver dyads to the Joint Home intervention (n=50) and usual care (n=50) arms. The aims of the study are: Aim 1: To test the preliminary efficacy of home-based, joint patient and caregive... Read More
Gender:
ALL
Ages:
Between 50 years and 120 years
Trial Updated:
06/24/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type 2 Diabetes
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Cholangiocarcinoma
Register for Updates
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
NCT03896620
Recruiting
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment. However, tissue biopsy collection can be challenging (depending on the location of the tumor), and this procedure poses physical risks to the patient. A tissue biopsy also needs to be recollected at various time points in order to assess if the patient is responding to treatment. In this project, the inves... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Sarcoma
Register for Updates